Tamiflu                                                                                                                      General, Technology, Production, Manufacturing Process, Marketing, Suppliers, Distributors                                                          Primary Information Services                                                        Home. Ordering Information. Contact

                                         Information @ a Glance
General
  • Tamiflu is an antiviral medicine to treat infection caused by influenza virus. Tamiflu does not prevent you from getting the flu. Tamiflu is used to treat seasonal or annual flu viruses.
  • Tamiflu belongs to a group of medicines called neuraminidase inhibitors.
  • Tamiflu (oseltamivir phosphate) is available as a capsule containing 75-mg oseltamivir for oral use, in the form of oseltamivir phosphate.

  • Tamiflu is indicated for the treatment of uncomplicated acute illness due to influenza infection in adults who have been symptomatic for no more than 2 days.

Technology

  • Naturally acquired and experimental influenza, treatment with Tamiflu did not impair normal humoral antibody response to infection.

  • Antiviral activity of Tamiflu was supported for influenza A and B by experimental challenge studies in volunteers who received intranasal inoculations of challenge strains of influenza virus.

  • Research capacity and many years of experience in drug development are clearly reflected in its success on the preparation of key components for Tamiflu and Relenza

  • Tamiflu is a flu treatment; it is not a flu vaccine. Though it has been demonstrated to be moderately effective against Avian Flu in laboratory experiments, it is only effective when taken within two days of flu symptoms appearing.

Applications

  • Tamiflu is used to treat or prevent influenza in adults and children over the age of one

  • In the treatment of flu, it can be used in patients who have the symptoms of flu, when the influenza virus is known to circulate in the community..

  • In the prevention of flu, Tamiflu must be started within two days of the contact with someone who has flu.

  • Tamiflu is given as one dose once a day for at least 10 days after contact with an infected person. When Tamiflu is used during a flu epidemic, this dose can be given for up to 6 weeks. The doses need to be lower in patients who have kidney problems.

Market

  • Roche announces today that it will have increased its own production capacity to produce 300 million treatments of Tamiflu annually. The expansion will be achieved by a further stepwise scale-up of Roche’s production network
  • The U.S. federal government reportedly has ordered 5.3 million courses of Tamiflu for the Strategic National Stockpile, however it would require approximately 70 million courses to cover 25 percent of the U.S. population.

Report

  • Tamiflu contains the active substance oseltamivir. Tamiflu is presented as grey and yellow hard capsules for oral use or as a powder to make up an oral suspension.

  • The effects of Tamiflu were first tested in experimental models before being studied in humans. In humans, Tamiflu has been compared to placebo in studies in the treatment of flu the effectiveness was measured using a score card where patients recorded their symptoms.

  • The Committee for Medicinal Products for Human Use (CHMP) decided that Tamiflu’s benefits are greater than its risks for the treatment and prevention of influenza, as an additional method in case of a pandemic or when the flu vaccines are not effective against the influenza virus causing the seasonal epidemic.

Entrepreneur who want the informations on "General, Technology, Production, Manufacturing Process, Marketing, Suppliers, Distributors " can                                                                                                                                                                        Order the CD ROM Today  

Primary Information Services
 21 Murugappan St, SwamyNagar Ext2, 
Ullagaram, Chennai - 600091, India.
 Phone: 91 44 22421080 
Email : informer@eth.net
Mobile numbers:9940043898, 9444008898  Fax : 91 44 22423753